Invention Grant
- Patent Title: Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
-
Application No.: US17559938Application Date: 2021-12-22
-
Publication No.: US11608383B2Publication Date: 2023-03-21
- Inventor: Brian Elliott , Tahamtan Ahmadi , Christopher W. L. Chiu , Esther C. W. Breij , Ida Hiemstra , Maria N. Jure-Kunkel
- Applicant: GENMAB A/S
- Applicant Address: DK Copenhagen V
- Assignee: GENMAB A/S
- Current Assignee: GENMAB A/S
- Current Assignee Address: DK Copenhagen V
- Agency: Nelson Mullins Riley & Scarborough LLP
- Agent Jane E. Remillard, Esq.; Christopher L. Frank
- Main IPC: A61K39/40
- IPC: A61K39/40 ; A61K39/395 ; C07K16/28 ; A61K31/454 ; C07K16/00
Abstract:
Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.
Public/Granted literature
- US20220144964A1 BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA Public/Granted day:2022-05-12
Information query
